Evidence map›Paper›PMID 29503888›Full record

ArticleAmerican journal of ophthalmology case reports2016

Electroretinographic improvement after rituximab therapy in a patient with autoimmune retinopathy.

Gunay Uludag, Sumru Onal, Serra Arf, Isil Sayman Muslubas, Fatih Selcukbiricik, Aylin Koc Akbay, Nil Molinas Mandel

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology case reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Retinal Function in Advanced Multiple Sclerosis.Investigative ophthalmology & visual science · 2024
    Observational
  4. Article
  5. Rituximab for non-infectious Uveitis and Scleritis.Journal of ophthalmic inflammation and infection · 2021
    Review
  6. An update on autoimmune retinopathy.Indian journal of ophthalmology · 2020
    Review
  7. Review
  8. Article
  9. Unilateral cancer-associated retinopathy: diagnosis, serology and treatment.Documenta ophthalmologica. Advances in ophthalmology · 2017
    Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Gunay UludagKoc University Hospital, Department of Ophthalmology, Istanbul, Turkey.
Sumru OnalKoc University School of Medicine, Department of Ophthalmology, Istanbul, Turkey.
Serra ArfIstanbul Retina Institute, Istanbul, Turkey.
Isil Sayman MuslubasIstanbul Retina Institute, Istanbul, Turkey.
Fatih SelcukbiricikKoc University School of Medicine, Division of Medical Oncology, Department of Internal Medicine, Istanbul, Turkey.
Aylin Koc AkbayKoc University Hospital, Department of Ophthalmology, Istanbul, Turkey.
Nil Molinas MandelKoc University School of Medicine, Division of Medical Oncology, Department of Internal Medicine, Istanbul, Turkey.
Koç University · TRAmerikan Hastanesi · TRIstanbul Retina Institute (Turkey) · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe the effect of rituximab on full-field electroretinography (ERG) in a patient with nonparaneoplastic autoimmune retinopathy (npAIR). OBSERVATIONS: A 58-year-old male patient with visual complaints, positive anti-retinal antibodies and negative work-up for cancer was diagnosed with npAIR. Visual acuity and ancillary tests were normal except abnormal ERG in both eyes. The patient was given one course of rituximab 375 mg/m CONCLUSIONS AND IMPORTANCE: Rituximab therapy led to marked improvement in full-field ERG readings and regression of symptoms was reported by the patient after rituximab infusions. The effect of rituximab in npAIR was objectively demonstrated with ERG.

Indexed as

Autoimmune retinopathyElectrophysiologyElectroretinographyNeoplasticNonparaneoplasticRituximab

Identifiers

PMID29503888
PMCPMC5757362
OpenAlexW2314049982

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.